{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:05:08Z","timestamp":1785269108459,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>End-stage kidney disease (ESRD) patients on dialysis face pronounced cardiovascular and metabolic risks due to disruptions in lipoprotein(a), phosphorus, potassium, uric acid, and lipid balance. Current therapeutic options offer limited capacity to address these multifaceted abnormalities. Niacin is unique in this regard, as it not only lowers lipoprotein(a) but also influences phosphorus and uric acid metabolism. This study evaluates the efficacy of niacin therapy in improving these biochemical markers, thereby addressing an important therapeutic gap in this vulnerable population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a randomized, controlled trial, 50 hemodialysis patients were divided into two groups of twenty-five each. The control group continued standard care, while the niacin group received 500 mg\/day niacin alongside standard therapy. Patients were followed for 3 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Systolic and diastolic blood pressure were stabilized by niacin administration, in contrast to the control group, where both parameters rose significantly. Phosphorus decreased significantly in the niacin group (5.59 to 4.85 mg\/dL, <jats:italic>P<\/jats:italic> = 0.0077), while increasing in controls. PTH levels decreased by 60% with niacin but rose by 41.6% in controls (<jats:italic>P<\/jats:italic> = 0.001). Potassium levels fell by 27% in the niacin group, whereas they rose by 23.9% in controls. Sodium remained stable with niacin but declined in controls. Uric acid levels rose sharply in controls but remained stable with niacin. Niacin significantly improved lipid profiles, notably reducing LDL (31.9% vs. 7.9%) and total cholesterol (13.3% vs. 3.7%). Although triglycerides and VLDL rose in both groups, these variations were not of statistical significance. Importantly, Lp(a) levels decreased by 11.4% in the niacin group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Niacin (500 mg\/day) offers significant cardiovascular and metabolic benefits for hemodialysis patients, supporting its role as an adjunctive therapy in managing ESRD-associated risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov\/<\/jats:uri>, NCT06406140<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1625417","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:28:40Z","timestamp":1759987720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting cardiovascular and metabolic risk modification in end stage renal disease (ESRD): a randomized controlled clinical trial on niacin\u2019s effects on lipoprotein(a) and biochemical markers in hemodialysis patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Amira Reda Muhammad","family":"Galal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Abdel Rhman","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammena Y.","family":"Binsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani S.","family":"Alrossies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hassan","family":"Elthakaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadir Mohamed","family":"Elsawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Al Kasaby","family":"Zalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"s03","DOI":"10.1590\/1806-9282.66.S1.3","article-title":"Chronic kidney disease.","volume":"66","author":"Ammirati","year":"2020","journal-title":"Rev Assoc Med Bras."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1142013","DOI":"10.3389\/fmed.2023.1142013","article-title":"Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: a cross-sectional study.","volume":"10","author":"Yin","year":"2023","journal-title":"Front Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12944-021-01546-1","article-title":"non-high-density lipoprotein cholesterol may predict the cardio-cerebrovascular risk in patients on maintenance hemodialysis.","volume":"20","author":"Luo","year":"2021","journal-title":"Lipids Health Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease.","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/life11040315","article-title":"Lipoprotein abnormalities in chronic kidney disease and renal transplantation.","volume":"11","author":"Barbagallo","year":"2021","journal-title":"Life."},{"key":"B6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment.","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/bmfj.2023.182013.1732","article-title":"Association of pre- and post-dialysis uric acid difference to left ventricular structural and functional disorders in maintenance hemodialysis patients.","volume":"40","author":"Mohamed","year":"2023","journal-title":"Benha Med J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e25819","DOI":"10.7759\/cureus.25819","article-title":"Interpretation of parathyroid hormone levels in renal impairment.","volume":"14","author":"Nwosu","year":"2022","journal-title":"Cureus."},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43162-021-00080-x","article-title":"The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial.","volume":"34","author":"Ahmed","year":"2022","journal-title":"Egypt J Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/0971-4065.161020","article-title":"Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease.","volume":"26","author":"Zahed","year":"2016","journal-title":"Indian J Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40265-018-0950-2","article-title":"Targeting gastrointestinal transport proteins to control hyperphosphatemia in chronic kidney disease.","volume":"78","author":"Fouque","year":"2018","journal-title":"Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ekir.2020.02.1028","article-title":"Current management of hyperkalemia in patients on dialysis.","volume":"5","author":"Bansal","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/MS9.0000000000001731","article-title":"Prevalence and clinical characteristics of hyperuricemia among patients with chronic kidney disease under haemodialysis in a tertiary care center: a cross-sectional study.","volume":"86","author":"Ayush","year":"2024","journal-title":"Ann Med Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12882-020-02037-8","article-title":"Assessment of the efficacy of hemodialysis on uric acid clearance in a sub-Saharan African population at the end stage kidney disease.","volume":"21","author":"Doualla","year":"2020","journal-title":"BMC Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.32947\/ajps.v20i3.764","article-title":"Clinical evaluation of niacin in hemodialysis patients with hyperphosphatemia as adjuvant to calcium carbonate.","volume":"20","author":"Mohammed","year":"2020","journal-title":"Asian J Pharm Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000362424","article-title":"Effect of niacin on FGF23 concentration in chronic kidney disease.","volume":"39","author":"Rao","year":"2014","journal-title":"Am J Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1436836","DOI":"10.3389\/fnut.2024.1436836","article-title":"Association of dietary niacin intake with all-cause and cardiovascular mortality of adult patients with chronic kidney disease in the United States: results from NHANES 1999\u20132018.","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Nutr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3109\/08860221003753323","article-title":"Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials.","volume":"32","author":"Ahmed","year":"2010","journal-title":"Ren Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J Lipid Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0895-7061(02)03196-5","article-title":"Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects.","volume":"16","author":"Gadegbeku","year":"2003","journal-title":"Am J Hypertens."},{"key":"B22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.jhh.1001099","article-title":"Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects.","volume":"14","author":"Kelly","year":"2000","journal-title":"J Hum Hypertens."},{"key":"B23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-4065.98751","article-title":"The effect of niacin on serum phosphorus levels in dialysis patients.","volume":"22","author":"Edalat-Nejad","year":"2012","journal-title":"Indian J Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.jrn.2024.02.005","article-title":"The effect of niacinamide supplementation on phosphate concentrations in dutch dialysis patients: a randomized crossover trial.","volume":"34","author":"Schepers","year":"2024","journal-title":"J Renal Nutr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10569","DOI":"10.34172\/npj.2022.10569","article-title":"Effect of niacin on phosphorus, calcium, parathormone and vitamin D levels in hemodialysis patients; a double-blinded randomized clinical trial.","volume":"12","author":"Najafabadi","year":"2023","journal-title":"J Nephropharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.05440517","article-title":"The effect of extended-release niacin on markers of mineral metabolism in CKD.","volume":"13","author":"Malhotra","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1016\/j.ekir.2019.05.887","article-title":"MON-097 The effect of nicotinic acid on serum phosphorus and lipid profile in maintenance hemodialysis patients.","volume":"4","author":"Ha Phan","year":"2019","journal-title":"Kidney Int Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.","volume":"28","author":"Adiels","year":"2008","journal-title":"Arteriosclerosis Thrombosis Vascular Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.33696\/Gastroenterology.1.015","article-title":"Pharmacologic therapy with niacin for nonalcoholic fatty liver disease (NAFLD): emerging evidence.","volume":"1","author":"Kashyap","year":"2020","journal-title":"Arch Gastroenterol Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.ekir.2021.03.270","article-title":"Pos-255 niacin lowers serum phosphate levels in nigerian chronic kidney disease patients. A randomized control trial.","volume":"6","author":"Edema","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ki.2014.383","article-title":"Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.","volume":"87","author":"Kalil","year":"2015","journal-title":"Kidney Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study.","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:28:41Z","timestamp":1759987721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1625417"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1625417","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"article-number":"1625417"}}